13504NVL-655-01OpenA Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)NCT05384626IndustryAdultTreatmentI/IILungReuss, JoshuaGeorgetown University Medical Center : Ashlyn Wallace; Lombardi Comprehensive Cancer Center : Ashlyn WallaceThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS- 10508Ashlyn WallaceAshlyn Wallace+1 202-687-4773AEW72@georgetown.edu
2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>